Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study

NCT01340885 Phase 4 COMPLETED Results posted

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Details

Lead sponsor	Oregon Health and Science University
Phase	Phase 4
Status	COMPLETED
Enrolment	9
Start date	2011-01
Completion	2013-01

Conditions

• Parkinson's Disease

Interventions

• Strattera
• Exelon
• Placebo

Primary outcomes

• Attention Network Effects — 6 weeks

Countries

United States